company background image
AMRN

AmarinNasdaqGM:AMRN Stock Report

Market Cap

US$2.1b

7D

4.9%

1Y

41.7%

Updated

26 Sep, 2021

Data

Company Financials +
AMRN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

AMRN Overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.

Amarin Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amarin
Historical stock prices
Current Share PriceUS$5.40
52 Week HighUS$3.84
52 Week LowUS$9.25
Beta2.24
1 Month Change-3.91%
3 Month Change16.38%
1 Year Change41.73%
3 Year Change-66.81%
5 Year Change69.28%
Change since IPO-99.10%

Recent News & Updates

Shareholder Returns

AMRNUS BiotechsUS Market
7D4.9%-2.3%0.1%
1Y41.7%26.0%35.3%

Return vs Industry: AMRN exceeded the US Biotechs industry which returned 26% over the past year.

Return vs Market: AMRN exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is AMRN's price volatile compared to industry and market?
AMRN volatility
AMRN Beta2.24
Industry Beta1.03
Market Beta1

Stable Share Price: AMRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: AMRN's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19891,000Karim Mikhailhttps://www.amarincorp.com

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers.

Amarin Fundamentals Summary

How do Amarin's earnings and revenue compare to its market cap?
AMRN fundamental statistics
Market CapUS$2.13b
Earnings (TTM)US$4.32m
Revenue (TTM)US$620.41m

494.5x

P/E Ratio

3.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMRN income statement (TTM)
RevenueUS$620.41m
Cost of RevenueUS$128.32m
Gross ProfitUS$492.09m
ExpensesUS$487.77m
EarningsUS$4.32m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.011
Gross Margin79.32%
Net Profit Margin0.70%
Debt/Equity Ratio0%

How did AMRN perform over the long term?

See historical performance and comparison

Valuation

Is Amarin undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMRN ($5.4) is trading below our estimate of fair value ($13.67)

Significantly Below Fair Value: AMRN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMRN is poor value based on its PE Ratio (494.5x) compared to the US Biotechs industry average (24.9x).

PE vs Market: AMRN is poor value based on its PE Ratio (494.5x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: AMRN is poor value based on its PEG Ratio (6.1x)


Price to Book Ratio

PB vs Industry: AMRN's PB Ratio (3.3x) is in line with the US Biotechs industry average.


Future Growth

How is Amarin forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

81.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRN's forecast earnings growth (81.2% per year) is above the savings rate (2%).

Earnings vs Market: AMRN's earnings (81.2% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AMRN's revenue (16.7% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: AMRN's revenue (16.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMRN is forecast to be unprofitable in 3 years.


Past Performance

How has Amarin performed over the past 5 years?

30.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMRN has a high level of non-cash earnings.

Growing Profit Margin: AMRN became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: AMRN has become profitable over the past 5 years, growing earnings by 30.2% per year.

Accelerating Growth: AMRN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AMRN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: AMRN's Return on Equity (0.7%) is considered low.


Financial Health

How is Amarin's financial position?


Financial Position Analysis

Short Term Liabilities: AMRN's short term assets ($996.0M) exceed its short term liabilities ($370.4M).

Long Term Liabilities: AMRN's short term assets ($996.0M) exceed its long term liabilities ($29.2M).


Debt to Equity History and Analysis

Debt Level: AMRN is debt free.

Reducing Debt: AMRN currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: AMRN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AMRN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Amarin current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Karim Mikhail (50 yo)

0.083

Tenure

Mr. Karim Mikhail serves as President, Chief Executive Officer and Director at Amarin Corporation plc since August 01, 2021 and served as its Senior Vice President and Commercial Head of Europe since Augus...


Leadership Team

Experienced Management: AMRN's management team is seasoned and experienced (5.5 years average tenure).


Board Members

Experienced Board: AMRN's board of directors are seasoned and experienced ( 11.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Amarin Corporation plc's employee growth, exchange listings and data sources


Key Information

  • Name: Amarin Corporation plc
  • Ticker: AMRN
  • Exchange: NasdaqGM
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.135b
  • Shares outstanding: 395.30m
  • Website: https://www.amarincorp.com

Number of Employees


Location

  • Amarin Corporation plc
  • Grand Canal Docklands
  • Block C
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 22:02
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.